AC
YMAB

Avestar Capital’s Y-mAbs Therapeutics YMAB Stock Holding History

Avestar Capital’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-10,000
Closed -$68.2K – 498
2023
Q4 		$68.2K Hold
10,000
– – 0.01% 380
2023
Q3 		$54.5K Hold
10,000
– – 0.01% 362
2023
Q2 		$67.9K Buy
+10,000
New +$74.9K 0.01% 328

Other funds holding YMAB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Avestar Capital's YMAB Position: Q1 2024 in Review

Avestar Capital sold out of Y-mAbs Therapeutics (YMAB) in Q1 2024, closing a stake of 10,000 shares — an estimated $68.2K sold.

Avestar Capital first reported a position in YMAB in Q2 2023 and held it in 3 quarters. The position peaked at $68.2K in Q4 2023. 96 funds tracked by Wall St. Rank hold YMAB as of Q1 2024.

  • Avestar Capital reported no remaining Y-mAbs Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Avestar Capital sold 10,000 Y-mAbs Therapeutics shares in Q1 2024, an estimated $68.2K.
  • Avestar Capital first reported a position in Y-mAbs Therapeutics in Q2 2023 and held it in 3 quarters.
  • Avestar Capital's Y-mAbs Therapeutics position peaked at $68.2K in Q4 2023.
  • 96 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q1 2024.

Based on Avestar Capital's 13F filing for Q1 2024, filed 10 May 2024.